The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review
Identifieur interne : 000079 ( 2020/Analysis ); précédent : 000078; suivant : 000080The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review
Auteurs : Alexis Nahama ; Roshni Ramachandran ; Alvaro Francisco Cisternas ; Henry JiSource :
- Medicine in Drug Discovery [ 2590-0986 ] ; 2020.
Abstract
Acute respiratory distress is one of the major causes of mortality associated with COVID-19 disease. Many patients will require intensive care with ventilatory support. Despite progress and best efforts, the mortality rates projected remain high. Historical data outlook points towards 80% expected fatality for patients progressing to advanced pulmonary disease, even when hospitalized in the intensive care unit. This is particularly true among the patient population over 65. Novel life-saving strategies are desperately needed to mitigate the high mortality that will be associated with the late stage SARS-CoV-2 viral infection associated with the fatal respiratory distress.
We hypothesize that the morbidity, severity of the disease, and underlying physiological events leading to mortality are closely linked to the TRPV1 expressing neuronal system (afferent/efferent neurons) in the lungs. TRPV1 expressing cells are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system and are modulating the processes associated with localized cytokine release (storm) and overall rapid disease progression.
We suggest that therapeutic approaches targeting TRPV1 containing nerve fibers in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.
Url:
DOI: 10.1016/j.medidd.2020.100033
PubMed: NONE
PubMed Central: 7147194
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000998
- to stream Pmc, to step Curation: 000998
- to stream Pmc, to step Checkpoint: 000054
- to stream Ncbi, to step Merge: 001467
- to stream Ncbi, to step Curation: 001467
- to stream Ncbi, to step Checkpoint: 001467
- to stream Main, to step Merge: 000079
- to stream Main, to step Curation: 000079
- to stream Main, to step Exploration: 000079
- to stream 2020, to step Extraction: 000079
Links to Exploration step
PMC:7147194Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review</title><author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name></author><author><name sortKey="Ramachandran, Roshni" sort="Ramachandran, Roshni" uniqKey="Ramachandran R" first="Roshni" last="Ramachandran">Roshni Ramachandran</name></author><author><name sortKey="Cisternas, Alvaro Francisco" sort="Cisternas, Alvaro Francisco" uniqKey="Cisternas A" first="Alvaro Francisco" last="Cisternas">Alvaro Francisco Cisternas</name></author><author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7147194</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147194</idno><idno type="RBID">PMC:7147194</idno><idno type="doi">10.1016/j.medidd.2020.100033</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000998</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000998</idno><idno type="wicri:Area/Pmc/Curation">000998</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000998</idno><idno type="wicri:Area/Pmc/Checkpoint">000054</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000054</idno><idno type="wicri:Area/Ncbi/Merge">001467</idno><idno type="wicri:Area/Ncbi/Curation">001467</idno><idno type="wicri:Area/Ncbi/Checkpoint">001467</idno><idno type="wicri:Area/Main/Merge">000079</idno><idno type="wicri:Area/Main/Curation">000079</idno><idno type="wicri:Area/Main/Exploration">000079</idno><idno type="wicri:Area/2020/Extraction">000079</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review</title><author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name></author><author><name sortKey="Ramachandran, Roshni" sort="Ramachandran, Roshni" uniqKey="Ramachandran R" first="Roshni" last="Ramachandran">Roshni Ramachandran</name></author><author><name sortKey="Cisternas, Alvaro Francisco" sort="Cisternas, Alvaro Francisco" uniqKey="Cisternas A" first="Alvaro Francisco" last="Cisternas">Alvaro Francisco Cisternas</name></author><author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name></author></analytic><series><title level="j">Medicine in Drug Discovery</title><idno type="eISSN">2590-0986</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Acute respiratory distress is one of the major causes of mortality associated with COVID-19 disease. Many patients will require intensive care with ventilatory support. Despite progress and best efforts, the mortality rates projected remain high. Historical data outlook points towards 80% expected fatality for patients progressing to advanced pulmonary disease, even when hospitalized in the intensive care unit. This is particularly true among the patient population over 65. Novel life-saving strategies are desperately needed to mitigate the high mortality that will be associated with the late stage SARS-CoV-2 viral infection associated with the fatal respiratory distress.</p><p>We hypothesize that the morbidity, severity of the disease, and underlying physiological events leading to mortality are closely linked to the TRPV1 expressing neuronal system (afferent/efferent neurons) in the lungs. TRPV1 expressing cells are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system and are modulating the processes associated with localized cytokine release (storm) and overall rapid disease progression.</p><p>We suggest that therapeutic approaches targeting TRPV1 containing nerve fibers in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Severe Outcomes Among Patients With Coronavirus Disease Covid United States February Arch" uniqKey="Severe Outcomes Among Patients With Coronavirus Disease Covid United States February Arch">Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Population Of Sensory Neurons Essential For Asthmatic Hyperreactivity Of Inflamed Airways Dimitri Tr Nkner" uniqKey="Population Of Sensory Neurons Essential For Asthmatic Hyperreactivity Of Inflamed Airways Dimitri Tr Nkner">Population of sensory neurons essential for asthmatic hyperreactivity of inflamed airways Dimitri Tränkner</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Cabral, L D" uniqKey="Cabral L">L.D. Cabral</name></author><author><name sortKey="Giusti Paiva, A" uniqKey="Giusti Paiva A">A. Giusti-Paiva</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list></list><tree><noCountry><name sortKey="Cisternas, Alvaro Francisco" sort="Cisternas, Alvaro Francisco" uniqKey="Cisternas A" first="Alvaro Francisco" last="Cisternas">Alvaro Francisco Cisternas</name><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name><name sortKey="Ramachandran, Roshni" sort="Ramachandran, Roshni" uniqKey="Ramachandran R" first="Roshni" last="Ramachandran">Roshni Ramachandran</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000079 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000079 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= PMC:7147194
|texte= The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |